---
figid: PMC3579607__onc0011311900003
figtitle: Mechanisms underlying anti-angiogenic therapy cardiotoxicity
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3579607
filename: onc0011311900003.jpg
figlink: /pmc/articles/PMC3579607/figure/F3/
number: F3
caption: 'Mechanisms underlying anti-angiogenic therapy cardiotoxicity. Inhibition
  of VEGF signaling with tyrosine kinase inhibitor-directed therapies impacts numerous
  signaling pathways resulting in inhibition of angiogenesis, and protein synthesis
  and degradation via the PI3K-Akt-NO pathway; and inhibition of cell proliferation
  and differentiation via the MAPK-ERK pathway. Monoclonal inhibitors include bevacizumab
  and ramucirumab; multikinase inhibitors include sunitinib, axitinib, pazopanib,
  motesanib, vadetanib, and sorafenib.Abbreviations: MAPK, mitogen-activated protein
  kinase; NO, nitric oxide; PI3K, phosphatidylinositol 3-kinase; VEGF, vascular endothelial
  growth factor.'
papertitle: The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly
  Targeted Cancer Therapeutics.
reftext: Jessica M. Scott, et al. Oncologist. 2013 Feb;18(2):221-231.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9574921
figid_alias: PMC3579607__F3
figtype: Figure
redirect_from: /figures/PMC3579607__F3
ndex: 3331e7ac-deca-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3579607__onc0011311900003.html
  '@type': Dataset
  description: 'Mechanisms underlying anti-angiogenic therapy cardiotoxicity. Inhibition
    of VEGF signaling with tyrosine kinase inhibitor-directed therapies impacts numerous
    signaling pathways resulting in inhibition of angiogenesis, and protein synthesis
    and degradation via the PI3K-Akt-NO pathway; and inhibition of cell proliferation
    and differentiation via the MAPK-ERK pathway. Monoclonal inhibitors include bevacizumab
    and ramucirumab; multikinase inhibitors include sunitinib, axitinib, pazopanib,
    motesanib, vadetanib, and sorafenib.Abbreviations: MAPK, mitogen-activated protein
    kinase; NO, nitric oxide; PI3K, phosphatidylinositol 3-kinase; VEGF, vascular
    endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TGFA
  - KDR
  - FLT1
  - FLT4
  - PDGFRB
  - PDGFRA
  - KIT
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - blo
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - MKP-4
  - p38b
  - rl
  - Erk7
  - Vandetanib
  - Pazopanib
  - Cancer
  - Lung cancer
---
